Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Maintenance in Advanced Soft Tissue Sarcoma
NCT02367651Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Jun 2015
- Primary completion
- May 2018
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pazopanib in soft tissue sarcoma (STS), sponsored by GSK. Planned start Jun 2015; status: withdrawn.
02
Drugs
pazopanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02367651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367651.